The system shows no signs of self-correcting without deliberate intervention.
For decades, the architecture of medical research has been built on an incomplete blueprint — one that systematically underweights the bodies, conditions, and suffering of half the world's population. A new analytical tool developed by the World Economic Forum and its partners has now made this imbalance legible: just one-fifth of global health R&D funding addresses conditions that disproportionately affect women, and fewer than three percent of clinical trials are designed to study women specifically. What presents itself as a gap in fairness is also, by any measure, a failure of collective rationality — one that costs the global economy an estimated trillion dollars and tens of millions of healthy life-years every year it goes uncorrected.
- A decade of health R&D data reveals that women's conditions are not merely underfunded — they are structurally deprioritized, with over half of available research money pooling in just two areas while conditions like heart disease and premenstrual syndrome languish far below their actual burden.
- The clinical trial pipeline is nearly blind to female biology: with fewer than 3% of trials designed around women, most treatments in use today were validated on evidence drawn predominantly from male bodies.
- The failure compounds itself — conditions that attract little funding rarely reach human trials, and those that do face slow, uncertain paths to market, as illustrated by 112 anxiety programs over ten years yielding only four launched products.
- The Women's Health Innovation Radar, built by the WEF alongside the Gates Foundation, Kearney, and Wellcome Leap, is now mapping these blind spots — identifying where evidence is thin, where funding is absent, and where intervention could accelerate progress.
- The stakes are concrete: closing this gap could prevent 75 million disability-adjusted life years annually and add $1 trillion to global GDP by 2040, but only if funding mechanisms, regulatory frameworks, and private investment strategies are deliberately realigned.
A new analytical instrument has done what years of advocacy could not fully accomplish: it has made the underfunding of women's health legible in numbers too large to dismiss. The Women's Health Innovation Radar, developed by the World Economic Forum alongside the Gates Foundation, Kearney Health Institute, and Wellcome Leap, examined ten years of data across ten high-impact conditions and arrived at a stark finding — only one-fifth of all health R&D spending flows toward conditions that disproportionately affect women.
The disparity is not evenly spread. More than half of that already-thin slice of funding concentrates in just two areas — ovarian cancer and menopause — leaving conditions like ischemic heart disease and premenstrual syndrome chronically starved relative to the suffering they cause. Men-specific conditions such as prostate cancer, by contrast, receive substantially greater investment, a pattern that reflects historical inertia more than any rational assessment of disease burden.
The problem extends beyond money. Fewer than three percent of clinical trials are designed to study how diseases manifest in women or how women respond to treatment, meaning that most medical evidence in use today was built on male biology. The pipeline compounds the problem: of 112 anxiety programs tracked over the decade, only four reached the market. Underfunding, inadequate clinical evidence, and poor translation into scalable products form a self-reinforcing loop that the system, left alone, shows no ability to break.
The economic argument for intervention is not abstract. Closing the innovation gap could generate 75 million disability-adjusted life years annually and contribute approximately one trillion dollars to global GDP by 2040. The radar is designed to make that opportunity visible — mapping where gaps persist and where targeted investment could accelerate change. But the tool is only a beginning. What the analysis ultimately reveals is that incomplete medical knowledge is not a problem for women alone; it is a structural weakness in health systems that affects everyone. Correcting it is not charity — it is the work of building medicine that actually works.
A new diagnostic tool has made visible what researchers have long suspected: the machinery of modern medicine is systematically starving women's health of resources. The Women's Health Innovation Radar, developed by the World Economic Forum alongside the Gates Foundation, Kearney Health Institute, and Wellcome Leap, analyzed a decade of data across ten high-impact conditions and found a stark imbalance. Just one-fifth of all health research and development funding flows toward studying conditions that disproportionately affect women. The finding is not merely a matter of fairness—it represents a trillion-dollar economic opportunity left on the table.
The funding gap is not evenly distributed across women's health. More than half of the available research money concentrates in just two areas: ovarian cancer and menopause. This leaves other conditions with enormous disease burdens—ischemic heart disease, premenstrual syndrome, and others—chronically underfunded relative to how many women they affect and how much suffering they cause. By comparison, men-specific conditions like prostate cancer receive substantially more investment than their female equivalents, a disparity that reflects historical research priorities rather than the actual burden of disease.
The problem runs deeper than funding alone. Clinical trials, the gold standard for validating treatments in human bodies, almost never include women-specific research. Fewer than three percent of all clinical trials are designed specifically to study how diseases manifest in women or how women respond to treatment. This means that for most conditions, doctors and patients are working with evidence gathered primarily from male biology. The gap in sex-specific understanding compounds over time: even when research does happen, it often fails to progress into actual human testing, and when it does, the path to a marketable product remains uncertain and slow. The radar identified 112 anxiety programs in development pipelines over the ten-year period, yet only four resulted in launched products.
These three problems—insufficient funding, inadequate clinical evidence, and the failure to translate research into scalable solutions—reinforce each other in a closed loop. Conditions that receive more money are more likely to advance to product development. Conditions that advance to product development attract more investment. Everything else falls further behind. Without deliberate intervention, the system shows no capacity to correct itself. Historical priorities calcify into permanent ones.
The economic case for change is substantial. Improving women's health outcomes could generate 75 million disability-adjusted life years annually—a measure of disease burden prevented—and add approximately one trillion dollars to global GDP by 2040. That figure encompasses not just direct medical benefits but the broader economic productivity of healthier populations. Yet the current system is structured in ways that make this opportunity invisible to investors and policymakers.
The radar itself is a tool for making the invisible visible. By mapping where evidence exists, where funding flows, and where gaps persist, it identifies priority areas for accelerated investment and development. But the tool alone cannot solve the problem. Closing the innovation gap requires systemic change: realignment of funding mechanisms, regulatory clarity that encourages rather than impedes women-focused research, stronger business cases that attract private investment, and leadership willing to challenge entrenched research priorities. It requires collaboration across sectors and borders, and policy frameworks agile enough to support innovation that is both safe and scalable.
What emerges from the radar's analysis is not a crisis unique to women's health, but a window into how all health systems fail when they operate on incomplete information. The conditions that affect women are not separate from the conditions that affect everyone. Better understanding of how disease manifests across different bodies, different hormonal states, and different life stages strengthens medicine for all patients. The trillion-dollar opportunity is not a gift to women—it is a correction toward a more functional, more equitable, and ultimately more prosperous health system.
Citações Notáveis
What is good for women's health is good for everyone.— World Economic Forum analysis
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that clinical trials are only three percent women-specific? Aren't the drugs the same regardless?
The biology isn't the same. Hormones, body composition, how organs metabolize drugs—these things differ. A treatment validated only in men might work differently, or worse, in women. We've learned this the hard way before.
So this is about past mistakes repeating?
It's about the present. Right now, a woman with heart disease is being treated based on evidence gathered mostly from men. We don't fully know if the dose is right, if the side effects will be different, if the treatment will work as well. That's not ancient history—that's today.
The radar found that ovarian cancer and menopause get more than half the funding. That seems reasonable—aren't those important?
They are important. But the radar is asking: important relative to what? Ischemic heart disease kills more women than any cancer. Premenstrual syndrome affects hundreds of millions. The funding doesn't match the burden of disease. It matches what researchers happened to study decades ago.
What would actually change if a trillion dollars started flowing toward women's health?
You'd see products designed from the ground up for women's bodies, not adapted from men's research. You'd see clinical evidence that actually applies to women. You'd see faster diagnosis, better treatment, fewer preventable disabilities. And you'd see a health system that works better for everyone.
Why hasn't this been fixed already?
Because the system doesn't see itself as broken. It sees itself as neutral. But neutrality that ignores half the population isn't neutral—it's a choice.